BC Platforms, Codigo46 Partner
News Jul 27, 2016
BC Platforms has announced that it has signed a partnership with Codigo46 focused on building and managing the largest biobank in Latin-America in co-operation with Mexican health and research specialists to deliver clinical patient benefits and future personalised medicines through academic and commercial research. This biobank, which is unique due to the Mexican genotype which has a native American and European mix, is expected to grow to over one million genotypic and phenotypic data samples over the next three years.
BC Platforms will deliver a bespoke technology platform enabling Codigo46’s global customers and collaborators to efficiently access and analyse this data without compromising its integrity. This platform will provide automated systems and high end infrastructure to enable the acquisition of large volumes of data from new sources. Codigo46 has adopted Illumina’s recently announced Infinium® Global Screening Array (GSA). The chip has been designed for genetic risk screening of large global populations.
Lorenza Haddad Chief Executive Officer at Codigo46, commented: “We are very excited to partner with BC Platforms. We believe that with their support and expertise we can achieve our ambitious goal to build the largest biobank in Latin America. Our ambitions are not just to generate a genetic database, but also to incorporate clinical data from hospital systems with patient consent and be a part of different research projects. It will be the first biobank to provide such extensive data sets from subjects of this diverse genotype and we expect it will be a highly valuable resource for academic and commercial research across the globe.”
Tero Silvola, Chief Executive Officer at BC Platforms, commented: “We feel privileged to collaborate with Codigo46 on this unique project and support the translation of these diverse samples into valuable data for academic and commercial research. We are excited to work in partnership to develop a bespoke technology platform to support them in their mission to build the largest biobank in Latin America.”
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Cellular Judge Rules on Fate of mRNAs under Sugar StressNews
A newly discovered protein, Puf5P, has been shown to arbitrate on which mRNAs are stored and which are destroyed.READ MORE
Peli BioThermal Hires Dominic Hyde as New VP of Crēdo™ on DemandNews
Radical expansion of global rental program includes adding staff, locations and doubling their container inventory.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018